SGLT2 inhibitors reduced the risk of cardiovascular death or hospitalization for heart failure by 28% compared to placebo in patients with chronic kidney disease.
Meta-Analysis
Do SGLT2 inhibitors reduce the risk of cardiovascular death or hospitalization for heart failure in patients with chronic kidney disease?
SGLT2 inhibitors significantly reduce the risk of cardiovascular death, hospitalization for heart failure, and all-cause death in patients with chronic kidney disease, without increasing serious adverse events or urinary tract infections, though they do increase reproductive tract infections.
Effect estimate: HR 0.72 (95% CI 0.66-0.78)
p-value: p=0.000
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are inconsistent results from studies on their uses. Therefore, to explore the cardiovascular protective effect of SGLT2 inhibitors in the CKD patient population, we conducted a systematic review and meta-analysis to evaluate the cardiovascular effectiveness and safety of SGLT2 inhibitors in this patient population. Method: We searched the PubMed® (National Library of Medicine, Bethesda, MD, USA) and Web of Science™ (Clarivate™, Philadelphia, PA, USA) databases for randomized controlled trials (RCTs) of SGLT2 inhibitors in CKD patients and built the database starting in January 2023. In accordance with our inclusion and exclusion criteria, the literature was screened, the quality of the literature was evaluated, and the data were extracted. RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and Stata® 17.0 (StataCorp LP, College Station, TX, USA) were used for the statistical analyses. Hazard ratios (HRs), odds ratios (ORs), and corresponding 95% confidence intervals (CIs) were used for the analysis of the outcome indicators. Results: Thirteen RCTs were included. In CKD patients, SGLT2 inhibitors reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HHF) by 28%, CVD by 16%. and HHF by 35%. They also reduced the risk of all-cause death by 14% without increasing the risk of serious adverse effects (SAEs) and urinary tract infections (UTIs). However, they increased the risk of reproductive tract infections (RTIs). Conclusion: SGLT2 inhibitors have a cardiovascular protective effect on patients with CKD, which in turn can significantly reduce the risk of CVD, HHF, and all-cause death without increasing the risk of SAEs and UTIs but increasing the risk of RTIs.
Chen et al. (Thu,) conducted a meta-analysis in Chronic kidney disease. SGLT2 inhibitors vs. Placebo was evaluated on Cardiovascular death or hospitalization for heart failure (HR 0.72, 95% CI 0.66-0.78, p=0.000). SGLT2 inhibitors reduced the risk of cardiovascular death or hospitalization for heart failure by 28% compared to placebo in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: